Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tyler's Departure As FDA Chief Counsel Leaves Another Chair To Fill

This article was originally published in The Tan Sheet

Executive Summary

Ralph Tyler is leaving FDA 18 months after taking the helm as the agency's chief counsel.

You may also be interested in...



People In Brief

Former FDA Chief Counsel Tyler joins Venable; Perrigo appoints de Velarde as regulatory affairs manager; USP shakes up its executive team; Neutra Corp. names Morrissey president and CEO; more people in brief

People In Brief

Former FDA Chief Counsel Tyler joins Venable; Perrigo appoints de Velarde as regulatory affairs manager; USP shakes up its executive team; Neutra Corp. names Morrissey president and CEO; more people in brief

FDA Congressional Relations, Internal Structure May Change With Sharfstein Exit

The departure of Principal Deputy Commissioner Josh Sharfstein provides FDA an opportunity to 
take stock of its relationship with Congress and to 
re-evaluate its organizational structure.

Related Content

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel